# Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia

> **NCT01518556** · PHASE1,PHASE2 · COMPLETED · sponsor: **Konkuk University Medical Center** · enrollment: 49 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** Idarubicin

## Key facts

- **NCT ID:** NCT01518556
- **Lead sponsor:** Konkuk University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2025-03
- **Final completion:** 2025-03
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-03-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01518556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01518556, "Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01518556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*